Clinical trials: Mild to Moderately Active Ulcerative Colitis
- Condition Mild to Moderately Active Ulcerative Colitis
- Funder type Industry (pharma, biotech, devices)
Ulcerative Colitis
Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)
The purpose of this trial is to investigate the efficacy of mesalamine for the induction of clinical and endoscopic remission in subjects with active, mild to moderate UC.
- Trial name
- NCT02522767
- Testing
- Mesalamine
- Where
- 93 sites in United States, Bulgaria and 9 more
- Volunteers
- 228 people
- Sponsor
- Ferring Pharmaceuticals
Proctitis, Proctosigmoiditis
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in participants who…
- Trial name
- NCT01008410
- Testing
- Budesonide
- Where
- 63 sites in United States
- Volunteers
- 265 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)
A 2-part study, comprising of a 36-week placebo-controlled period (PCP) and a 24-week open-label extension (OLE) period, to assess the efficacy and safety of 2 dose regimens of GB004 when added to background UC therapy of…
- Trial name
- NCT04556383
- Testing
- GB004
- Where
- 77 sites in United States, Georgia and 7 more
- Volunteers
- 236 people
- Sponsor
- GB004, Inc.
Acute Ulcerative Colitis
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
The purpose of this research study was to compare the medication TP05 to the medication Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and tolerability of TP05.
- Trial name
- Precision-UC (NCT01903252)
- Testing
- TP05, Asacol 400 mg
- Where
- Switzerland
- Volunteers
- 817 people
- Sponsor
- Tillotts Pharma AG
Ulcerative Colitis
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects…
- Trial name
- NCT04314375
- Testing
- Low Dose Budesonide, High Dose Budesonide
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bausch Health Americas, Inc.
Healthy Adult Volunteers, Active Ulcerative Colitis
A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis
This Phase 1b/2a clinical development plan is focused on the use of NP-201 acetate injection to investigate the pharmacokinetics (PK), safety, efficacy, PD (pharmacodynamic) markers (Phase 1b) and tolerability of NP-201 acetate…
- Conditions
- Healthy Adult Volunteers, Active Ulcerative Colitis, Active Ulcerative Colitis (UC)
- Trial name
- NCT06681389
- Testing
- NP-201 acetate injection (Part A)
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- NIBEC Co., Ltd.
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis
Phase 1B randomized, double-blind, placebo-controlled, two-cohort clinical trial of ABI-M201 in adult subjects with mildly-to-moderately active Ulcerative Colitis(UC) and ongoing treatment with mesalamine.
- Trial name
- NCT03923478
- Testing
- ABI-M201
- Where
- 11 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- Assembly Biosciences
Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single-dose TD-3504 and single dose 15N2-tofacitinib in healthy subjects and subjects with UC.
- Trial name
- NCT03103412
- Testing
- TD-3504, 15N2-tofacitinib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Ulcerative Colitis (UC)
LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)
A Phase 1b study to evaluate the safety and tolerability of LIV001 in Patients with Mild-to- Moderate Active Ulcerative Colitis
- Trial name
- NCT06749795
- Testing
- LIV001
- Where
- Poland
- Volunteers
- 15 people
- Sponsor
- Liveome Inc.
Mild to Moderate Ulcerative Colitis
A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis
The objectives of this bioequivalence study in patients with ulcerative colitis (UC) were: To establish the therapeutic equivalence of mesalamine delayed release tablet (MDRT) and Asacol Delayed Release Tablets 2.4 g per day (800…
- Trial name
- NCT01045018
- Testing
- Mesalamine
- Sponsor
- EMET Pharmaceuticals, LLC
Ulcerative Colitis
A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis
The purpose of the study is to obtain a first clinical assessment of the safety of dersalazine sodium in ulcerative colitis patients with mild to moderate disease.
- Trial name
- NCT00808977
- Testing
- Dersalazine sodium, Mesalazine
- Where
- 22 sites in Belgium, Hungary and 2 more
- Volunteers
- 80 people
- Sponsor
- Palau Pharma S.L.U.
Ulcerative Colitis
New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis
The purpose of this study is to establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately…
- Trial name
- NCT00269438
- Testing
- 5 ASA, enemas, suppositories, corticosteroids
- Where
- 66 sites in United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
A placebo controlled study of two doses of HMPL-004 in patients with active mild to moderate ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy subscore of 2-3, taking mesalamine (or equivalent) as a…
- Trial name
- NCT01805791
- Testing
- HMPL-004 1800 mg/day, HMPL-004 2400 mg/day
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Hutchison Medipharma Limited
Ulcerative Colitis
A Study of LIV001 in Healthy Subjects and Those with Mild-to-Moderate Active Ulcerative Colitis (UC)
This study is only for the first in human phase 1a study designed to investigate the safety and tolerability of LIV001 in healthy participants.
- Trial name
- NCT05975047
- Testing
- LIV001
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Liveome Inc.
Ulcerative Colitis
A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative Colitis
- Trial name
- ECO-RESET (NCT03759041)
- Testing
- Vancomycin Pre-Treatment, SER-287
- Where
- 93 sites in United States, Canada
- Volunteers
- 203 people
- Sponsor
- Seres Therapeutics, Inc.
Colitis, Ulcerative
To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis
To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild to moderate active ulcerative colitis after 8 weeks of treatment.
- Trial name
- NCT03412682
- Testing
- Budesonide (6 mg), Budesonide (9 mg), Mesalazine (3,600 mg)
- Where
- 72 sites in Japan
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Mild to Moderate Ulcerative Colitis
Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis
A clinical trial is being conducted to test the effects of a potential new treatment in patients with ulcerative colitis. Study participants will be given capsules containing either ORE1001 or a matching placebo capsule and will…
- Trial name
- NCT01039597
- Testing
- ORE1001
- Where
- 7 sites in Canada, India
- Volunteers
- 50 people
- Sponsor
- Ore Pharmaceuticals, Inc.
Proctitis, Proctosigmoiditis
Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
The purpose of this study is to establish the efficacy profile of rectally administered budesonide foam, as compared to an equivalent volume of rectally administered placebo foam over the same dosing schedule, in participants who…
- Trial name
- NCT01008423
- Testing
- Budesonide
- Where
- 62 sites in United States
- Volunteers
- 281 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis
This is a proof of concept, randomized, open label, 2-arm study of OPRX-106 in subjects with active mild to moderate ulcerative colitis.
- Trial name
- NCT02768974
- Testing
- OPRX-106
- Where
- 7 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Protalix
Ulcerative Colitis
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
This study is to compare the efficacy and safety of budesonide MMX 9 mg versus placebo as add-on therapy to an existing oral 5-ASA regimen for the induction of remission in participants with active mild or moderate ulcerative…
- Trial name
- NCT01532648
- Testing
- Budesonide MMX®, 5-ASA
- Where
- 114 sites in United States, Bulgaria and 9 more
- Volunteers
- 510 people
- Sponsor
- Bausch Health Americas, Inc.